SCHEMBL12377964

SCHEMBL12377964

CC(=O)c1ccc2nc(-c3cn(C)c4ccccc34)[nH]c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.66
MAPT P10636 2/20 0.66
KDM4E B2RXH2 1/20 0.66
NPC1 O15118 1/20 0.66
ALDH1A1 P00352 1/20 0.66
LMNA P02545 1/20 0.66
HPGD P15428 1/20 0.66
TSHR P16473 1/20 0.66
HTT P42858 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
HSD17B10 Q99714 1/20 0.66
HDAC6 Q9UBN7 3/20 0.48
CHEK2 O96017 6/20 0.47
GRK2 P25098 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20088774 0.88 HDAC6 (0.64) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL2292684 0.88 KDM4E (0.62) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL2287559 0.85 ALDH1A1 (0.58) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL2287568 0.77 KDM4E (0.58) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL19982678 0.75 CHEK2 (0.74) HDAC6CHEK2HDAC3HDAC1HDAC8
SCHEMBL23745062 0.75 RAB9A (0.51) RAB9AMAPTHDAC6CHEK2HDAC3
SCHEMBL23745079 0.75 CHEK2 (0.47) RAB9AMAPTHDAC6CHEK2HDAC3
SCHEMBL2292691 0.73 KDM4E (0.54) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL14091496 0.73 BRD4 (0.46) RAB9AMAPTKDM4ENPC1ALDH1A1
SCHEMBL23744819 0.73 HDAC6 (0.47) RAB9AMAPTSMN1; SMN2HDAC6CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257547-B1 NOVEL BENZIMIDAZOLE LINKED PYRROLOÝ2,1-QÝ1,4¨BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2015-08-05 EP disclosed
US-8835421-B2 Benzimidazole linked pyrrolo[2,1-c[1,4] benzodiazepine hybrids as potential antitumour agents and process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2014-09-16 US disclosed
US-20110190268-A1 Novel Benzimidazole Linked Pyrrolo[2,1-c[1,4] Benzodiazepine Hybrids as Potential Antitumour Agents and Process for the Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190268-A1 Novel Benzimidazole Linked Pyrrolo[2,1-c[1,4] Benzodiazepine Hybrids as Potential Antitumour Agents and Process for the Preparation Thereof GABRA1, GABRA4, PBRM1 RAB9A 2355/4885MAPT 3772/4885KDM4E 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.